Phase 2 N=260 Leprosy Skin Test Antigens Trial
Leprosy
Primary: Number of Participants With Reactions to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Microgram — 0; 3; 1; 5…
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=94,127 Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar
Leprosy
Primary: Compare Effectiveness in Curbing Transmission of Leprosy of Three Different Approaches of Post Exposure Prophylaxis — 1.04; 1.42; 0.98; 0.92 number of new cases per 1000…
Phase 2 N=313 Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2)
Leprosy
Primary: Mean Difference in QTc Interval Between the Two Arms 24 Hours After Treatment Administration — 396.81; 397; 404.61; 394.06 msec
N/A N=72 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India
Lymphatic Filariasis
Primary: Dermatology Life Quality Index (DLQI) Domain Scores — 3; 0; 1; 0 units on a scale
Phase 2 N=111 Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB
Tuberculosis, Multidrug-Resistant
Primary: Time to Sputum Culture Conversion — 5.9; 6.3; 6.1; 6.1 weeks
Phase 2 N=92 Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World
Cutaneous Leishmaniasis
Primary: Complete Clinical Response (CCR) of Lesion at Days 50, 100 and 180 (+7 Days) — 47; 30; 3; 12 Participants
Phase 3 N=375 Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)
Cutaneous Leishmaniasis
Primary: Final Clinical Cure Rate — 101; 102; 73 participants — p=0.0001
Phase 3 N=399 Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama
Cutaneous Leishmaniasis
Primary: Percent of Participants With Final Clinical Cure — 78.6; 77.8 percent of participants
Phase 3 N=118 Impact of Community Scabies Treatment on Head Lice Prevalence in the Solomon Islands
Scabies · Head Lice
Primary: Number of Participants With Headlice — 3 Participants
Phase 2 N=30 Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama
Leishmaniasis, Cutaneous
Primary: Number of Participants Who Obtained Final Clinical Cure of Index Lesion — 9; 13 Participants
Phase 4 N=11 Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy
Generalized Lipodystrophy
Primary: Evaluate the Immunogenicity Associated With Daily Subcutaneous (SC) Metreleptin Treatment in Patients With Congenital Generalized Lipodystrophy (CGL) or Acquired…
Phase 4 N=1,291 Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
Scabies · Yaws · Impetigo
Primary: Impetigo Prevalence at 12 Months — 79; 66; 20; 12 Cases of impetigo
Phase 3 N=437 Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia.
Cutaneous Leishmaniasis
Primary: Complete Clinical Response — 85; 103; 86 participants
Phase 2 N=4 Miltefosine to Treat Mucocutaneous Leishmaniasis
Mucosal Leishmaniasis · Cutaneous Leishmaniasis
Primary: Number of Participants With Clinical Cure of Lesions — 3 Participants